High Court clears UK puberty-blocker trial to enroll over 200 gender-questioning youths

The High Court rejected a judicial review brought by gender-care campaigners, permitting the Pathways trial to recruit more than 220 children aged 11 to 16 beginning 1 August. Run by King's College London and funded by NHS England, the study will assess puberty-blocking drugs that pause physical changes such as breast development and voice deepening. Participants must already be receiving specialist gender services and will undergo extensive medical and psychological evaluations, with safeguards tightened after the Medicines and Healthcare products Regulatory Agency raised safety concerns.

The trial will monitor outcomes like bone density, brain development, fertility and mental wellbeing. Critics, including the Bayswater Support Group, parents and former blocker user Keira Bell, argued the design lacked sufficient protection and questioned informed consent. The judge concluded none of the challenges were likely to succeed, emphasizing that each child would have been assessed for a reasonable prospect of clinical benefit.